Imexhs Ltd · ASX:IME
Imexhs — Investor Presentation (February 2023)
25 slides from Imexhs's investor presentation, Feb 28, 2023
Slide 1: FY22 Results
FY22 Results Presenters 28 February 2023 Dr German Arango, CEO Reena Minhas, CFO
Slide 2: Agenda
Agenda FY22 Results 1. IMEXHS Overview 2. FY22 Results Overview 3. FY22 Financials 4. Strategy & Outlook 2
Slide 3: Overview
imexHSs Overview
Slide 4: One Company with two businesses aimed at democratising access to medical expertise
One Company with two businesses aimed at democratising access to medical expertise Medical Imaging Software Radiology Services Provider of innovative, cloud-based, Outsourcing of imaging facilities medical imaging software solutions and teleradiology to hospitals and medical facilities 4
Slide 5: Expanding global footprint
Expanding global footprint Software 18 countries; 449 sites 3,000+ radiologists 35 distributors in 15 countries Radiology Colombia, Spain and Mexico 35 radiology centres 150+ in-house radiologists 5
Slide 6: FY22 Results Overview
ime «Hs FY22 Results Overview
Slide 7: Business Highlights
Business Highlights • The Company has demonstrated the scalability of the business across different geographies with an attractive product and disruptive business model and now is focused in generating positive earnings and cashflow. • Focus is on sales within Latin America and those product develop
Slide 8: FY22 Operational Highlights
FY22 Operational Highlights • Successful implementation of a cost • Awarded new expanded 3-year contract reduction plan completed with major hospital group Colsubsidio, for the outsourcing of its entire radiology • Continued sales momentum for IMEXHS services network at increased prices and Cloud wi
Slide 9: Path to Profitability
Path to Profitability • Cost out project had the effect of decreasing run rate operating and software capex costs by circa $250k per month with the view to moving company to cash positive • Market and product development projects that did not have a clear pathway to profitability were halted. Commen
Slide 10: FY22 Financial Highlights
FY22 Financial Highlights Sales Revenue1 Annual Recurring Revenue (ARR) EBITDA Up 28% yoy $17.1m Down 4% yoy $19.7m vs ($3.0m) in FY21 ($0.8m) Up 34% on a constant Up 8% on a constant currency basis3 currency basis Debt Closing cash Underlying EBITDA2 Vs $2.4m at 31 $1.1m vs $4.2m at 31 $1.9m vs ($1
Slide 11: FY22 Business Unit Results
FY22 Business Unit Results • Software primarily relates to sales of $M Software Radiology Corporate Total IMEXHS Enterprise and growing IMEXHS Cloud business Revenue 6.4 10.7 - 17.1 ➢ Revenue up 28% yoy ➢ ARR up 30% Underlying 1.1 0.7 (1.9) (0.1) • Radiology includes RIMAB along with EBITDA other se
Slide 12: Software IMEXHS Enterprise
Software IMEXHS Enterprise Number of Studies (m) +33% • Enterprise imaging platform tailored to a 10.0m customer’s specific needs (formerly AQUILA Custom) • Dedicated to large university hospitals and 7.5m multi-site healthcare organisations • Pricing determined by volume-based tiers • IMEXHS Enterp
Slide 13: Software IMEXHS Cloud
Software IMEXHS Cloud • Standardised radiology solution launched in Annualised Recurring Revenue ($’000) and # May 2020; unique and successful offering in of contracts 3,500 an underpenetrated global market 4000 180 2,800 160 • Provides small and medium-sized customers 3500 2,500 140 with low-cost,
Slide 14: Radiology Services
Radiology Services • Outsourced radiology services for hospitals and other establishments • includes administration, technicians, enterprise software, training, equipment if required; radiologists located on premise and internal 35 Radiology Centres teleradiology • 95%+ of revenues • Teleradiology s
Slide 15: FY22 Financials
imex<«Hs FY22 Financials
Slide 16: Progress in ARR
Progress in ARR +8% on a constant currency basis) Constant currency basis assumes that historic results are converted at the 31 Dec-22 exchange rate. This removes the impact of changes in currency rates and allows comparison of IMEXHS’s underlying operating performance. ARR as at 31 December 2022 •
Slide 17: Income Statement
Income Statement $'000 FY22 FY21 Var Var % • FY22 P&L reflects full year of RIMAB acquisition versus 3 months in FY21 Revenue 17,117 13,373 3,745 28% • Revenue of $17.1m, up 28% yoy and Other revenue 174 71 103 144% 34% on a constant currency basis Total revenue 17,292 13,444 3,847 29% • Recurring r
Slide 18: Balance Sheet
Balance Sheet $'000 Dec 22 Jun 22 Dec 21 Cash 1,912 856 4,186 • Closing cash balance of $1.9m as at 31 Trade & other receivables 6,503 7,286 6,412 December 2022 and Net Assets of $15.9m Inventories 97 78 84 Current assets 8,511 8,220 10,682 • Intangible assets include Goodwill of Trade & other recei
Slide 19: Summary Cash Flow
Summary Cash Flow $'000 FY22 FY21 • Closing cash balance of $1.9m as at 31-Dec-22 Net cash used in operating activities (2,198) (2,968) • Debt of $1.1m at 31-Dec-22, down from $2.4m at Net cash used in investing activities (2,222) (3,386) 31 Dec-21. Net cash flow from financing activities 2,252 (162
Slide 20: Strategy & Outlook
imexHs Strategy & Outlook
Slide 21: Software development
Software development Strategy & Priorities Delivered in 2022 • DICOM and Modality Worklist Gateway:v1.2 new • Prioritize high impact development, product, no longer hardware, now delivered as to increase margins, revenue, reduce software reducing speed of installation, seamless integration with moda
Slide 22: FY23 Outlook
FY23 Outlook Our Plan To be delivered through: ● Cost out project aimed at moving to cash ● To be cash positive positive and balance sheet sustainability ● Focused geographically for ● Focus on Latam countries – traction and 2023 cost of doing business ● Software development to ● Development project
Slide 23: Q&A
Q&A
Slide 24: Disclaimer
Disclaimer The information contained in this Presentation or subsequently provided to the Recipient of this Presentation, whether orally or in writing by or on behalf of ImExHS Limited or its respective employees, agents or consultants (“Information”) is provided to the Recipient on the terms and co
Slide 25: FY22 Results
FY22 Results 28 February 2023